Neurology

Generalized Myasthenia Gravis

Expert Roundtables Podcast: FcRn Inhibitors for Generalized Myasthenia Gravis

by Neelam Goyal, MD; James F. Howard Jr, MD

Overview

With their rapid onset of effect and fairly narrow adverse-event profile, FcRn inhibitors have been transformational in the management of generalized myasthenia gravis (gMG). As noted by our experts in today’s podcast, they can be used as a bridge therapy to longer-acting immunosuppressives, a rescue therapy for an acute deterioration, or on a more chronic basis for those with gMG who have not fully responded to their initial treatment.

References

Akhtar M, Akhtar M, Farooqi HA, et al. Efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: an updated systematic review and meta-analysis. Clin Neurol Neurosurg. 2025;254:108910. doi:10.1016/j.clineuro.2025.108910

Antozzi C, Vu T, Ramchandren S, et al; Vivacity-MG3 Study Group. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Heo YA. Efgartigimod alfa in generalised myasthenia gravis: a profile of its use. CNS Drugs. 2023;37(5):467-473. Published correction appears in CNS Drugs. 2023;37(5):475.

Li J, Wu X, Chu T, et al. The efficacy and safety of FcRn inhibitors in patients with myasthenia gravis: a systematic review and meta-analysis. J Neurol. 2024;271(5):2298-2308. doi:10.1007/s00415-024-12247-x

Matic A, Bril V. Rozanolixizumab for myasthenia gravis: a breakthrough treatment and future prospects. Immunotherapy. 2025;17(5):309-316. doi:10.1080/1750743X.2025.2491295

Zhu LN, Hou HM, Wang S, et al. FcRn inhibitors: a novel option for the treatment of myasthenia gravis. Neural Regen Res. 2023;18(8):1637-1644. doi:10.4103/1673-5374.363824

Profile

Neelam Goyal, MD

Clinical Professor of Neurology and Neurological Sciences
Division of Neuromuscular Medicine
Interim Vice Chair of Advancement, Community and Engagement and Wellbeing Director
Department of Neurology
Communication Coach, Neurology Residency Program
Stanford University School of Medicine
Stanford, CA

Profile

James F. Howard Jr, MD

Professor of Neurology, Medicine, and Allied Health
Director, Myasthenia Gravis Clinical Trials and Translational Research Program
Former James F. Howard Distinguished Professor of Neuromuscular Disease
Former Chief, Neuromuscular Disorders Division
The University of North Carolina at Chapel Hill School of Medicine
Chapel Hill, NC